|
A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA). |
|
|
Honoraria - Celgene; Janssen-Cilag; Onyx |
Consulting or Advisory Role - Celgene; Janssen; Onyx; Pharmacyclics |
Research Funding - Genesis Pharmaceuticals; Janssen |
Travel, Accommodations, Expenses - Celgene; Genesis Pharmaceuticals; Onyx |
|
|
|
Consulting or Advisory Role - Janssen |
Travel, Accommodations, Expenses - Janssen |
|
|
Consulting or Advisory Role - Celgene; Millennium |
Speakers' Bureau - Celgene; Millennium; Onyx; Seagen |
Research Funding - Celgene (Inst) |
|
|
Honoraria - Celgene; Lundbeck; Roche Pharma AG |
Consulting or Advisory Role - Celgene; Lundbeck; Roche Pharma AG |
Research Funding - Lundbeck; Roche Pharma AG |
|
|
Research Funding - Celgene |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
Consulting or Advisory Role - Celgene; Janssen |
Expert Testimony - Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Janssen; Novartis; Pharmacyclics; Takeda |
Consulting or Advisory Role - Amgen; Takeda |
Research Funding - Novartis; Takeda |
Travel, Accommodations, Expenses - Janssen |
|
|
|
Research Funding - Amgen; Biotest; Gilead Sciences; Onyx; Pfizer; Pharmacyclics; Spectrum Pharmaceuticals |
|
|
Consulting or Advisory Role - Abbvie; Genentech; Gilead Sciences; Pharmacyclics |
Speakers' Bureau - Genentech; Gilead Sciences; Pharmacyclics |
Research Funding - GlaxoSmithKline; NCCN |
|
|
No Relationships to Disclose |
|
|
Research Funding - Infinity Pharmaceuticals; Pharmacyclics; Roche Pharma AG |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Gilead Sciences |
|
|
Consulting or Advisory Role - Janssen |
Research Funding - Amgen; GlaxoSmithKline; Mundipharma |
Travel, Accommodations, Expenses - GlaxoSmithKline; Mundipharma; Roche Pharma AG; Sanofi |
|
|
Employment - Pharmacyclics |
|
|
Employment - Pharmacyclics |
|
|
Employment - Pharmacyclics |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Pharmacyclics |
|
|
Honoraria - Janssen; Pharmacyclics |
Consulting or Advisory Role - Janssen; Onyx; Pharmacyclics |
Research Funding - Janssen; Onyx; Pharmacyclics |
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute |
|
|
Consulting or Advisory Role - Gilead Sciences; Janssen; Pfizer; Roche Pharma AG |
Speakers' Bureau - Gilead Sciences; Janssen; Pfizer; Roche Pharma AG |
Research Funding - Janssen; Roche Pharma AG |